Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v3.21.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash Flows from Operating Activities:      
Net loss $ (16,829) $ (17,855) $ (21,516)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:      
Depreciation and amortization 499 982 945
Loss on disposal of assets, net     1,228
Provision for bad debts 1,328 1,695 469
Provision for sales returns 87    
Provision for inventory excess and obsolescence (591) 413 166
Inventory write-offs and disposals 1,300 15 128
Amortization of discount on lines of credit 165 140 202
Amortization of debt issuance costs 331 188 126
Change in fair value of warrants (5,850)    
Issuance costs for common stock warrants 1,641    
Loss on patent litigation settlement     1,500
Stock-based compensation 3,370 2,742 2,768
Warrants issued to consultants   48  
Deferred income taxes   7 (27)
Earned interest income   2 1
Changes in operating assets and liabilities:      
Accounts receivable 4,286 655 (1,458)
Inventory (871) 825 (255)
Prepaid expenses and other current assets 825 439 (25)
Accounts payable and accrued liabilities (2,107) (3,156) 1,762
Deferred revenue (379) 114 (161)
Net cash and cash equivalents used in operating activities (12,795) (12,746) (14,147)
Cash Flows from Investing Activities:      
Purchases of property, plant, and equipment (96) (207) (558)
Proceeds from disposal of property, plant, and equipment     36
Net cash and cash equivalents used in investing activities (96) (207) (522)
Cash Flows from Financing Activities:      
Proceeds from the issuance of common stock and June 2020 Warrants 6,912 9,171  
Proceeds from the issuance of Series F Convertible Preferred Stock 2,700    
Proceeds from the issuance of July 2020 Warrants 15,300    
Payments of equity offering costs (1,281) (821) (164)
Payment of July 2020 Warrant issuance costs (1,640)    
Principal payments under capital lease obligation     (46)
Borrowings on other long-term loans 3,140    
Borrowings under term loan   2,500 12,500
Principal payment on term loan (700)    
Borrowings on credit facility 3,000   3,696
Payments of credit facility (3,000)   (3,696)
Payments of debt issuance costs (128) (133) (1,058)
Proceeds from the exercise of common stock warrants 46    
Proceeds from exercise of stock options   4 3
Net cash and cash equivalents provided by financing activities 24,349 10,721 11,235
Effect of exchange rate changes 317 (23) (106)
Increase (decrease) in cash and cash equivalents 11,775 (2,255) (3,540)
Cash, cash equivalents and restricted cash, beginning of year 6,101 8,356 11,896
Cash, cash equivalents and restricted cash, end of year 17,876 6,101 8,356
Supplemental cash flow disclosure:      
Cash paid for interest 1,881 1,784 23
Cash received for interest 11    
Cash paid for income taxes 22 35 44
Cash paid for operating leases 489 797  
Non-cash accrual for capital expenditures   18 31
Non-cash settlement of performance award liability 151 201  
Non-cash right-of-use assets obtained in exchange for lease obligations 2,037 276  
Equity financing costs in accounts payable 74 129  
Deemed dividend on preferred stock 17,378    
Loss on patent litigation settlement     1,500
Forgiveness of debt 10    
Receivable from warrants exercised and included in prepaid and other current assets 1,498    
Warrants issued in connection with debt instruments $ 67 $ 161 $ 847